Transcript Toxicological Emergencies in the Oncology Patient

Toxicological Emergencies in the
Oncology Patient: Antidotal Therapies
2008 ACMT Pre-Meeting Symposium
Rama B. Rao, MD
NYCPCC
NYPH-Weill-Cornell Medical Center
Methotrexate and
Carboxypeptidase G2
GLUCARPIDASE
FOLATE METABOLISM
Dihydrofolate
reductase (DHFR)
Tetrahydrofolate (THF)
Folate
N5,N10-Methylene-THF
N10-Formyl-THF
Homocysteine
dUMP
dTMP
(DNA synthesis)
N5-Methyl-THF
IMP
(purines
de novo synthesis)
S-Adenosylmethionine
(Methylation of proteins,
lipids, RNA and DNA)
Methotrexate
Dihydrofolate
reductase (DHFR)
Tetrahydrofolate (THF)
Folate
N5,N10-Methylene-THF
N10-Formyl-THF
Homocysteine
dUMP
dTMP
(DNA synthesis)
N5-Methyl-THF
IMP
(purines
de novo synthesis)
S-Adenosylmethionine
(Methylation of proteins,
lipids, RNA and DNA)
Methotrexate
• Neoplasms
• Fetal cells
• Disorders of
– Immune system
– Rheumatology
– Dermatology
Methotrexate Toxicity
Scheinfeld N. Three cases of toxic skin eruptions associated with methotrexate…Derm Online
Journal 2006;12(7):15.
Not for publication. For educational use only.
Systemic Methotrexate Toxicity
•
•
•
•
Mucositis, stomatitis
Dermatitis
GI distress
Hematologic/Immunosuppression
• Organ dysfunction
– Hepatitis
– Pulmonary
– Renal
Scheinfeld N. Derm Online Journal
2006;12(7):15.
Not for publication. For educational use only.
Risk Factors: MTX Toxicity
• Renal Impairment
– Medication interactions
– Failure
• Overdose
• Idiosyncratic:
– Wide differences in concentrations with
administration of 1 gm/m2 IV
Smith S, et al. J Med Tox 2008;4(2):132-140; Evans WE, et al. Clinical pharmacodynamics
of high dose methotrexate in acute lymphocytic leukemia. Identification of a relation
between concentration and effect. New Engl J Med 1986;314(8):471-477.
Identifying Systemic Methotrexate
Toxicity
• Known overdose
• Therapeutic monitoring plasma levels:
– Therapeutic
– Toxicity
< 1 M/L at 48 hours
> 1 M/L at 48 hours
> 10 M/L at 24 hours
• Clinical findings: Manifest over a few days
Wang 2006, Howland 2006
Leucovorin
Bypass inhibited
pathways
Infectious
vigilance1
Hydration
GCSF
1. Moisa 2006
Supportive
Decrease MTX
Concentrations
NaHCO3
Invasive therapy
Leucovorin
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Dose to ≥ MTX plasma concentration
100 mg/m2 IV Q 6 hours
NEVER INTRATHECALLY
Continue treatment in severely ill
patients until there is evidence of
recovery
Decrease MTX
Concentrations
NaHCO3
Invasive therapy
Mechanism of methotrexate
Methotrexate
Dihydrofolate
reductase (DHFR)
Tetrahydrofolate (THF)
Folate
N5,N10-Methylene-THF
N10-Formyl-THF
Homocysteine
dUMP
dTMP
(DNA synthesis)
N5-Methyl-THF
IMP
(purines
de novo synthesis)
S-Adenosylmethionine
(Methylation of proteins,
lipids, RNA and DNA)
Leucovorin
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Decrease MTX
Concentrations
NaHCO3
Enhances solubility
Leucovorin
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Decrease MTX
Concentrations
NaHCO3
Invasive therapy
HD/HP
Leucovorin
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Decrease MTX
Concentrations
NaHCO3
Invasive therapy
GLUCARPIDASE
Glucarpidase (CPDG2)
• FDA approved as single use Investigational New Drug
for compassionate therapy
• Dosing for systemic methotrexate toxicity
– 50 u/kg IV over 5 minutes
• 70 patients reduction of methotrexate concentrations by
98% at 15 minutes
• Adverse events in 329 patients:
– Flushing, hypersensitivity, pruritis
– HTN, dysrhythmias?
Package Insert Glucarpidase, O’Marcaigh 1996. Schwartz S et
al.Oncologist 2007; 12:1299-1308; Snyder 2007
Methotrexate
GLUCARPIDASE
OH
DAMPA
Glutamate
Glucarpidase Limitations
• DAMPA
– Low solubility in urine
• Continue alkalinization of urine
– Affects methotrexate assays
• Use HPLC post treatment to follow MTX
• Cleaves leucovorin
– Allow 2-4 hour interval between medications
– Current investigation
– Continue therapy for 48 hours after glucarpidase
• Availability: HD/HP while awaiting
Schwartz S et al.Oncologist 2007; 12:1299-1308
Glucarpidase Limitations
• DAMPA
– Low solubility in urine
• Continue alkalinization of urine
– Affects methotrexate assays
• Use HPLC post treatment to follow MTX
• Cleaves leucovorin
– Allow 2-4 hour interval between medications
– Current investigation
– Continue therapy for 48 hours after glucarpidase
• Availability: HD/HP while awaiting
Schwartz S et al.Oncologist 2007; 12:1299-1308
IV Glucarpidase Indications
•
•
•
•
Advanced signs of clinical toxicity
Persistently elevated MTX concentrations
Clcr ≤ 60 mL/min/m2
Patient with a combination of:
– Renal failure
– On leucovorin
– Plasma MTX concentration > 10M/L at 24
hours
Package insert. Widemann 2004.
Intrathecal Methotrexate
Toxicity
CSF Methotrexate Toxicity
• Within 60 minutes to a few hours
– Headache
– Vomiting
– Altered mentation
– Seizure
– Apnea
– CV instability
– Death
Ettinger 1985;Jakobson 1992,Finkelstein 2004
Leucovorin IV
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Decrease MTX
Concentrations
IV NaHCO3
Invasive therapy
CSF drainage/
irrigation/perfusion
CSF Drainage
• Remove up to 94% of MTX if drainage
occurs within first 15 minutes
• Diminishes to 30-40% if performed at 2
hours
Riva 1999, O’Marcaigh 1996, Jakobson 1992, Widemann 2004.
Leucovorin IV
Bypass inhibited
pathways
Infectious
vigilance
Hydration
GCSF
Supportive
Decrease MTX
Concentrations
IV NaHCO3
Invasive therapy
CSF drainage/
irrigation/perfusion
IT GLUCARPIDASE
Intrathecal Glucarpidase
• Non-human primate model of intrathecal
MTX overdose
– 400 fold decrease in CSF concentrations
within 5 minutes of administration
• No primate deaths
Adamson 1991
Intrathecal Glucarpidase
• Human data
– 7 patients 155 mg – 600 mg MTX
– Included 4 children ages 5-9
– All received:
• Drainage (some with perfusion)
• Intravenous Leucovorin
• Intrathecal Glucarpidase within 5 hours
Widemann 2004
Indications?
• May depend on intrathecal MTX dosage
and symtoms:
– Less than 100 mg: many adults will respond
well to drainage and IV leucovorin alone
– Between 100 mg and 500 mg MTX have
variable outcomes
– One survivor of 1200 mg IT MTX without
glucarpidase
Consider IT Glucarpidase
• Severe CNS symptoms
• Consider when dosage of MTX is > 100
mg
• Ideal patient is yet to be defined
• Dosing: 2 vials IT (1000 units/vial)
standard for adults or children after initial
drainage
IV/IT Glucarpidase
• Adjunctive therapy in methotrexate
overdose
• May obviate the need for:
– HD/HP in systemic toxicity
– Ventricular-lumbar perfusion in IT toxicity
• Prevention is key
DEXRAZOXANE
Extravasations of
Chemotherapy
1.
3.
2.
1.
NEIS 2. Schulmeister 3. Sauerland
Not for publication. For educational use only.
Chemotherapy Extravasations
• Incidence
– 0.1- 6%
– Unknown for intrathoracic
• Retrospective study at a major cancer center
– <0.01%
Sauerland 2006, Khan 2002, Langenstein 2002
Chemotherapy Extravasations
• Recent prospective study, 36 centers in 5
countries in Europe
– Time period and total number of
administrations not reported
– 80 potential extravasation cases
Mouridsen 2007
Natural History
•
•
•
•
•
•
•
•
Fullness, induration
Resistance to flushing the line
Pain
Redness
Blistering
Discoloration
Necrosis
Full thickness skin loss
Kretschmar 2006, Stein 1997, Mayo 1998, Loth 1991, Eom 2005, Linder 1985
Chemotherapy Classification
• Irritants
• Vesicants
Irritants
Class
Examples
Alkylating agents
Carmustine, ifosfamide
Platinum analogs
Carboplatin, cisplatin
Topoisomerase II inhibitors
Etoposide
? Liposomal anthracyclines
Goolsby 2006, Schrijvers 2003, Wang 2006, NEIS discussion forum
Irritant
Oxaliplatin
Kretzschmar A. Clin Onc 2003;21(21):4068-4069
Not for publication. For educational use only.
Wood LS Am J Nursing 1993
Vesicants
• Non DNA-binding
• DNA binding
Goolsby 2006, Schrijvers 2003, Wang 2006
Non-DNA Binding Vesicants
Class
Example
Vinca alkaloids
Vincristine, vinblastine
Taxane
Paclitaxel
Non-classical
alkylator
Amsacrine
Goolsby 2006, Schrijvers 2003, Wang 2006
Non-DNA Binding Vesicants
Doxcetaxel
El Saghir NS. Anticancer Drugs
2004;15:401-404.
Not for publication. For educational use only.
Non-DNA Binding Vesicants
Vinblastine
Viale PH. Sem Onc Nuring 2006;22(3):144-151.
Not for publication. For educational use only.
DNA Binding Vesicants
Class
Alkylating agents
Examples
Mechlorethamine
Antitumor antibiotics
Dactinomycin
Anthracyclines
Doxorubicin, daunorubicin
Doxorubicin effects on
human hepatoma cells.
Eom YW. Oncogene 2005;24:2765
Not for publication. Educational use only.
Mechanism DNA Binding
Vesicants
• Enter nucleus
• Bind nucleic acids
– Inhibit topoisomerase II
– Precipitate multiple DNA strand breaks
– Free radical formation through
• Semiquinones
• Iron
• Apoptosis/mitotic catastrophe
Schulmeister 2007, Sauerland 2006, Eom 2005
Re-release
DNA Binding Vesicants
Sauerland C. Onc Nursing Forum 2006
Not for publication. For educational use only.
Doxorubicin Extravasation
Courtesy of Lisa Schulmeister
Not for publication. For educational use only.
Liposomal Doxorubicin
Courtesy of Lisa Schulmeister
Not for Publication. For educational use only.
Oncology Nursing Society
• Strongly urges training of providers
administering anti-neoplastic agents
• Major cancer centers have similar, if
not identical guidelines
Risk Factors for Extravasation
• Untrained personnel
– 33/38 extravasations during
administration by housestaff, faculty
physicians or substitute nurses
Linder 1985
DNA Binding Vesicants
D’Andrea Scand J Plast Recon Surg 2004.
Not for publication. For educational use only.
DNA Binding Vesicants
D’Andrea Scand J Plast Recon Surg 2004.
Not for publication. For educational use only.
Training
• Selection/assessment of access site
– Order and placement of peripheral attempts
• Checklists:
– Tourniquet removal
– Patient education
– Assessment
• Central lines, infusion pumps, bolus dosing
• Response to patient complaints
• Assumption of extravasation when in
doubt
Schulmeister 2006, Sauerland 2006
Training
• Selection/assessment of access site
– Order and placement of peripheral attempts
• Checklists:
– Tourniquet removal
– Patient education
– Assessment
• Central lines, infusion pumps, bolus dosing
• Response to patient complaints
• Assumption of extravasation when in
doubt
Schulmeister 2006, Sauerland 2006
DNA Binding Vesicants
Doxorubicin extravasation.
Rudolph R. J Clin Onc 1987.
Not for publication. For educational use only.
Less Preventable Risk Factors
• Sudden movement from vomiting
• Use of agents that cause sedation
• Patient co-morbidities or prior sequelae
from chemotherapy
• Proximal scarring or thrombosis
Schulmeister 2006, Sauerland 2006, Mayo 1998
Central Line Risk Factors
• Catheter migration or fracture
• Multiple attempts
• Perforation of vessel
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997,
Crues 2002, Lokich 1999, Leong 1996
Intrathoracic Extravasations
• Mediastinitis
• Effusions
– Pleural
– Pericardial
• Phrenic nerve palsy
• Protracted cough
• Fatality
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997,
Crues 2002, Lokich 1999, Leong 1996; Schulmeister L. A complication of vascular
access device insertion. J Intravenous Nursing 1998;21:197-202.
Chest Wall Extravasation
• Extrusion from venotomy
site
• Inadequate placement of
line in relation to SVC
• Fibrin sheath formation
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997,
Crues 2002, Lokich 1999, Leong 1996
Fibrin Sheath Formation
Mayo DJ. Supp Care Cancer 1998.
Not for publication. For educational use only.
Doxorubicin extravasation with neuropathy at 2 months.
Disa JJ et al. 1998
Not for publication. For educational use only.
Extremity Extravavasations:
Clinical Consequences
•
•
•
•
•
Prolonged morbidity
Multiple surgeries
Septicemia
Poor mobility
Delay of
chemotherapy
• Compartment
syndrome
•
•
•
•
•
•
Contractures
Scarring
Lymphedema
Recall reactions
Chronic pain
Quality of life issues
Kumar 2001, Linder 1985, Sauerland 2006, Anderson 1996, Bozkurt 2003, Durhsen 1997,
Quintanar Verdugues 2008
Consequence or Coincidence?
• A patient survives early diagnosis of
adenocarcinoma of stomach
• Tumor formation on the dorsum of her hand
which was diagnosed as squamous cell
carcinoma
Lauvin 1995
Consequence or Coincidence?
• The site of extravasation of doxorubicin ten
years prior
• Lymph node metastases
• Patient died within 16 months of diagnosis
1Lauvin
1995
Extravasation
Differential Diagnosis
• Flare reaction
– Local irritation
– Streaking
– Phlebitis
• Recall reaction
Wood 1993, Cox 1984, Wickham 2006, Valencak 2007, Saini 2006, Susser 1999,
Shapiro 1994, Schulmeister 2006
Recall Reaction
• Proper intravenous administration causes
irritation, swelling and even blistering at a
remote site of previous:
– Radiation
– Extravasation of the same agent
• Can occur weeks to years after initial injury
Wood 1993, Cox 1984, Wickham 2006, Valencak 2007, Saini 2006, Susser 1999,
Shapiro 1994, Schulmeister 2006, Du Bois 1996
Saini A. Recall inflammatory skin reaction after use of
pegylated liposomal doxorubicin in site of previous
drug extravasation. Lancet Oncol 2006;7:186-187.
Not for publication. For educational use only.
Management Extravasations
Initial Management
• Leave access in place and attempt to
withdraw any extravasant
• Debate regarding flushing the area with
saline
– Recommended for intrathoracic
extravasations
• Remove line
Conundrum: Anthracyclines
• Most of the event is subcutaneous
• Injury is delayed
• Outcome can be severe with up to 33%
tissue necrosis
Kretschmar 2006, Stein 1997, Mayo 1998, Loth 1991, Eom 2005, Linder 1985
Options for Anthracycline
Extravastions
• Wait and watch
– Persistent pain after 2 weeks
– OR for resection of necrotic tissue
– Disadvantage:
• Waiting for necrosis
• May require prolonged hospitalization or
revisitations
• Some re-opening and debridement thereafter not
uncommon
– Advantage:
• Some will recover without requiring resection
Option:
Anthracycline Extravasation
• Aggressive Surgery
– Assume the evolution of necrosis will occur
– Perform wide excision early to avoid
progression
• Advantage: prevent the pain and
debilitation of necrosed tissue
• Disadvantage: Invasive, not always
necessary
Identifying Injured Tissue
• Anthracyclines bind to nucleic acids
• Can be identified by fluorescence
microscopy of biopsy specimens1
• Negative specimens did not develop
necrosis2
Dahlstrom1 1990; Andersson2 AP et al. 1993.
Intermediate Therapy
• Fluoresence microscopy of biopsy
specimens
• Resection of positive specimens
• Disadvantage: Still invasive
Mouridsen 2007, Andersson 1993, Schulmeister 2007, Scott Ely, MD Personal
communication.
Dexrazoxane
Vd = 22 - 36 L/m2
Distribution in total
body water.
42% elimination in
urine
No protein binding
Dexrazoxane
• FDA Approved September 2007 for
extravasations of anthracyclines
• Previously approved by FDA for use of
limiting cardiotoxicity from anthracyclines
in patients with >300 mg/m2 cumulative
dose
Schucter 2002, Schulmeister 2008
DEXRAZOXANE
Schulmeister 2008, Langer 2000
Dexrazoxane Metabolism
Dexrazoxane
Hasinoff BB. 2008;17(2):21-233
Fe binding
metabolite
Mechanism Anthracycline Injury
• Enter nucleus
• Bind nucleic acids
– Inhibit topoisomerase II
– Precipitate multiple DNA strand breaks
– Free radical formation through
• Semiquinones
• Iron
• Apoptosis/mitotic catastrophe
Schulmeister 2007, Sauerland 2006, Eom 2005
Re-release
Animal Model: Dexrazoxane
• Mice receive SC administration of an
anthracycline (AC) or H2O2 or saline
• Followed by systemic dexrazoxane
• Reduction of tissue lesions of AC
• No reduction of H2O2 lesions
Langer 2000
Dexrazoxane in Humans
• Sporadic case reports
– Epirubicin
– Doxorubicin
– No surgeries
– Some delay to therapy
Bos AM, et al., Acta Oncologica 2001.
Not for publication. For educational use only.
POST USE DEZRAZOXANE
Langer 2000 (letter), Bos 2001, Jensen 2003 Frost 2006, El Saghir 2004, Uges 2006
Dexrazoxane: Prospective
Study
• Prospective multi-center, multi-country
• Well defined criteria for enrollment
• Sequential observation, single arm, open
label
• Administration of dexrazoxane not delayed
• Outcome measures: decrease in surgeries
Mouridsen 2007
Dexrazoxane Study Results
• 80 patients identified
• 53 of 54 were assessable
• Reduction in surgery at one arm of study
by 100%
• Only one patient required surgery
Mouridsen 2007
Dexrazoxane Study: Adverse
Events
•
•
•
•
Pain at infusion site
Nausea, vomiting up to 18.8% in one wing
Wound infections
Transient elevations in LFTs
Mouridsen 2007
Dexrazoxane Study Limits
• Relation to makers of dexrazoxane
• Design might by default reduce surgeries in
some places where immediate surgical
evaluation was standard. (single armed
investigation)
• Design might enhance vigilance and limit extent
of injury
Mouridsen 2007
Strengths
• Well defined criteria for injury
– Study Size
– Diagnosis
• Clinically relevant, biopsy proven exposures
– 4 patients had intrathoracic extravasations
Mouridsen 2007
Dexrazoxane for Extravasation
• Administered < 6 hours of extravasation
– 1000 mg/m2 IV first dose over 2 hours not to exceed 2000
mg
– 1000 mg/m2 IV at 24 hours over 1-2 hours, max 2000 mg
– 500 mg/m2 IV at 48 hours over 1-2 hours, max 1000 mg
• Adjust in creatinine clearance administering 50% of
the above doses for CLCR < 40 mL/min
– Urinary excretion 42%
Hasinoff 2008, Package Insert Dexrazoxane
Dexrazoxane
• Three makers in USA
– Generic
– Patent holders for prevention of cardiotoxicity
– Patent holders for extravasation
• Dosing is higher for extravasations than
for prevention of cardiotoxicity
American Society of Health Systems Pharmacists 25 August 2008
Dexrazoxane
• Three makers in USA
– Generic Unknown Cost. Available September 2008
– Patent holders for prevention of cardiotoxicity
$513.08 for 500 mL of reconstituted solution
Available November 2008
– Patent holders for extravasation $14,750
• Dosing is higher for extravasations than
for prevention of cardiotoxicity
American Society of Health Systems Pharmacists 25 August 2008
Dexrazoxane
• Adverse events
– Nausea, vomiting, LFT abnormalities,
myelosuppression, phlebitis
• Contraindications
– Pregnant/nursing/children?
• No concomitant use of topical DMSO
– Based on animal model
• No data on buffering
Hasinoff 2008; Hooke MC. J Ped Onc Nursing 2005;22:261-264 Lipshultz SE, et al. The
effect of dexrazoxane on myocardial injury. New Engl J Med 2004;351:145-152.
Jensen JN. Dexrazoxane – a promising antidote in the treatment of
accidental extravasation of anthracyclines. Scand J Plastic and Recon
Sur Hand Surg 2003;37:3:174-175.
Not for publication. For educational use only.
Outstanding Questions
• Role in liposomal extravasations
• If/When to administer to children and at
what dosing
• Need for biopsy?
• Role in intrathoracic extravasations
Hooke MC. J Ped Onc Nursing 2005;22:261-264., Lipshultz SE, et al. The effect of
dexrazoxane on myocardial injury. New Engl J Med 2004;351:145-152
Summary
• Prevention is key
• Fluorescence
microscopy should be
the gold standard for
identifying at-risk tissue
• Further evaluations of
the safety and utility of
dexrazoxane are
indicated
• The current data is
promising
Bos AM, et al., Acta Oncologica 2001.
Not for publication. For educational use only.
POST USE DEZRAZOXANE
Disclosure/Information
• I have no financial conflicts of interest to report.
• Syllabus
Material on extravasation
• “Grab and go” section of clinically relevant articles
– Summary sheet on carboxypeptidase G2
• Recent relevant publications
• How to access medication
J Med Tox 2008;4(2):132-140
Acknowledgements
• Major Urban Cancer Centers in NYC
• Lisa Schulmeister, RN
• Scott Ely, MD, MPH
• Faculty, NYC Poison Control Center
• ACMT